{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:05:30Z","timestamp":1782853530983,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017804","name":"City of Hope","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008237","name":"Department of Surgery","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008237","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.omto.2023.100734","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T11:24:02Z","timestamp":1697714642000},"page":"100734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases"],"prefix":"10.1016","volume":"31","author":[{"given":"Annie","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyambabu","family":"Chaurasiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony K.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-In","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuman","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6676-0593","authenticated-orcid":false,"given":"Yanghee","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2023.100734_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.790150","article-title":"Oncolytic Virotherapy: From Bench to Bedside","volume":"9","author":"Yang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omto.2023.100734_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9040419","article-title":"Oncolytic Virotherapy for Cancer: Clinical Experience","volume":"9","author":"Chaurasiya","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.omto.2023.100734_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.coi.2018.03.008","article-title":"Oncolytic viruses and immunity","volume":"51","author":"Chaurasiya","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.omto.2023.100734_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.835300","article-title":"Oncolytic Virotherapy in Peritoneal Metastasis Gastric Cancer: The Challenges and Achievements","volume":"9","author":"Shao","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.omto.2023.100734_bib5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.omto.2020.10.002","article-title":"Novel Chimeric Poxvirus CF17 Improves Survival in a Murine Model of Intraperitoneal Ovarian Cancer Metastasis","volume":"19","author":"Hammad","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2023.100734_bib6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12967-018-1483-x","article-title":"Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose","volume":"16","author":"O'Leary","year":"2018","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.omto.2023.100734_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101404","article-title":"The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study","volume":"47","author":"Morgan","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.omto.2023.100734_bib8","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/CM9.0000000000001490","article-title":"A brand new era of cancer immunotherapy: breakthroughs and challenges","volume":"134","author":"Bai","year":"2021","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.omto.2023.100734_bib9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/14728222.2021.1971195","article-title":"Emerging therapeutic targets for gastric cancer from a host-Helicobacter pylori interaction perspective","volume":"25","author":"Abdi","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.omto.2023.100734_bib10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ags3.12060","article-title":"Treatment of patients with peritoneal metastases from gastric cancer","volume":"2","author":"Kitayama","year":"2018","journal-title":"Ann. Gastroenterol. Surg."},{"key":"10.1016\/j.omto.2023.100734_bib11","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ijc.28373","article-title":"Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors","volume":"134","author":"Thomassen","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omto.2023.100734_bib14","first-page":"61","article-title":"Establishment of cultured cell lines derived from a human gastric carcinoma","volume":"48","author":"Sekiguchi","year":"1978","journal-title":"Jpn. J. Exp. Med."},{"key":"10.1016\/j.omto.2023.100734_bib15","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.1158\/1078-0432.CCR-05-0729","article-title":"Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers","volume":"11","author":"Sakakura","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2023.100734_bib16","doi-asserted-by":"crossref","first-page":"6220","DOI":"10.1158\/0008-5472.CAN-05-0639","article-title":"Introduction of Sd(a) carbohydrate antigen in gastrointestinal cancer cells eliminates selectin ligands and inhibits metastasis","volume":"65","author":"Kawamura","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2023.100734_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jjco\/18.1.15","article-title":"Effect of human epidermal growth factor on cell growth and its receptor in human gastric carcinoma cell lines","volume":"18","author":"Ochiai","year":"1988","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.omto.2023.100734_bib18","first-page":"2773","article-title":"Characteristics of cell lines established from human gastric carcinoma","volume":"50","author":"Park","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2023.100734_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4143\/crt.2005.37.1.1","article-title":"Biology of SNU cell lines","volume":"37","author":"Ku","year":"2005","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.omto.2023.100734_bib20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","article-title":"Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study","volume":"88","author":"Sadeghi","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.omto.2023.100734_bib21","first-page":"CD004064","article-title":"Chemotherapy for advanced gastric cancer","author":"Wagner","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.omto.2023.100734_bib22","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2023.100734_bib23","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1200\/JCO.2002.08.105","article-title":"Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer","volume":"20","author":"Ross","year":"2002","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2023.100734_bib24","first-page":"1","article-title":"Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy","volume":"14","author":"Goldie","year":"1987","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.omto.2023.100734_bib25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/jso.22017","article-title":"Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity","volume":"104","author":"Gill","year":"2011","journal-title":"J.\u00a0Surg. Oncol."},{"key":"10.1016\/j.omto.2023.100734_bib26","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1245\/s10434-013-3061-z","article-title":"Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States","volume":"21","author":"Turaga","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.omto.2023.100734_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.864647","article-title":"Gastric Cancer With Peritoneal Metastasis-A Comprehensive Review of Current Intraperitoneal Treatment Modalities","volume":"12","author":"Prabhu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omto.2023.100734_bib28","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/jgm.800","article-title":"Oncolytic virotherapy for cancer treatment: challenges and solutions","volume":"7","author":"Davis","year":"2005","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omto.2023.100734_bib29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/CMR.0000000000000180","article-title":"Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study","volume":"25","author":"Doni\u0146a","year":"2015","journal-title":"Melanoma Res."},{"key":"10.1016\/j.omto.2023.100734_bib30","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/apm.12576","article-title":"Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports","volume":"124","author":"Alberts","year":"2016","journal-title":"APMIS"},{"key":"10.1016\/j.omto.2023.100734_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2020.100639","article-title":"Oncolytic virotherapy: Challenges and solutions","volume":"45","author":"Goradel","year":"2021","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.omto.2023.100734_bib32","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.2147\/OTT.S63049","article-title":"Oncolytic viruses as immunotherapy: progress and remaining challenges","volume":"9","author":"Aurelian","year":"2016","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.omto.2023.100734_bib33","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s40259-022-00553-7","article-title":"Teserpaturev\/G47Delta: First Approval","volume":"36","author":"Frampton","year":"2022","journal-title":"BioDrugs."},{"key":"10.1016\/j.omto.2023.100734_bib34","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1380764","article-title":"Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T\u00a0cells targeting PSCA+ metastatic prostate cancer","volume":"7","author":"Priceman","year":"2018","journal-title":"Oncoimmunology"}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770523000839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770523000839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:26:15Z","timestamp":1762496775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770523000839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":32,"alternative-id":["S2372770523000839"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2023.100734","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2023.100734","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"100734"}}